Saudi firm Abdul Latif Jameel Health in alliance with Evelo of US on COVID-19 therapeutic medicine
Gulf News reported that Abdul Latif Jameel Health has struck a partnership with US’ Evelo Biosciences to ‘develop and commercialize’ the latter’s inflammation product in the Middle East, Turkey and Africa.
The product candidate – ‘EDP1815’ – could also have its use as a therapeutic medicine for COVID-19. EDP1815 is an “investigational oral medicine” and Evelo is conducting a Phase 2 clinical trial for the treatment of psoriasis, as well as two trials in patients hospitalized with COVID-19. Evelo recently reported positive Phase 1b data in treating atopic dermatitis.
Read the full article in its original location here.